181 related articles for article (PubMed ID: 26184685)
21. Dyslipidaemia: No limit to the benefits of LDL-cholesterol lowering.
Lim GB
Nat Rev Cardiol; 2015 Aug; 12(8):444. PubMed ID: 26099842
[No Abstract] [Full Text] [Related]
22. IMPROVE-IT: what have we learned?
Banach M; Nikolic D; Rizzo M; Toth PP
Curr Opin Cardiol; 2016 Jul; 31(4):426-33. PubMed ID: 27218683
[TBL] [Abstract][Full Text] [Related]
23. Proof That Lower Is Better--LDL Cholesterol and IMPROVE-IT.
Jarcho JA; Keaney JF
N Engl J Med; 2015 Jun; 372(25):2448-50. PubMed ID: 26039520
[No Abstract] [Full Text] [Related]
24. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
Blazing MA; Giugliano RP; Cannon CP; Musliner TA; Tershakovec AM; White JA; Reist C; McCagg A; Braunwald E; Califf RM
Am Heart J; 2014 Aug; 168(2):205-12.e1. PubMed ID: 25066560
[TBL] [Abstract][Full Text] [Related]
25. Ezetimibe plus simvastatin cardiovascular outcomes study program.
Padial LR
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):17-25. PubMed ID: 18095904
[TBL] [Abstract][Full Text] [Related]
26. The Effects of Lipid-Lowering Therapy on Serum Eicosapentaenoic Acid to Arachidonic Acid Ratio: An HIJ-PROPER Sub-Analysis.
Arashi H; Yamaguchi J; Kawada-Watanabe E; Otsuki H; Sekiguchi H; Ogawa H; Hagiwara N
J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):548-555. PubMed ID: 32567339
[TBL] [Abstract][Full Text] [Related]
27. Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White J; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2016 Mar; 133(13):e463. PubMed ID: 27022050
[No Abstract] [Full Text] [Related]
28. Applicability of the IMPROVE-IT Trial to Current Patients With Acute Coronary Syndrome: An NCDR Research to Practice Project.
Maddox TM; Tang F; Downs JR; Masoudi FA; Virani SS; Daugherty SL; Rumsfeld JS
JAMA Intern Med; 2017 Jun; 177(6):887-889. PubMed ID: 28437531
[TBL] [Abstract][Full Text] [Related]
29. Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT).
Sharma A; Sun JL; Lokhnygina Y; Roe MT; Ahmad T; Desai NR; Blazing MA
Am J Cardiol; 2019 Apr; 123(8):1193-1201. PubMed ID: 30739657
[TBL] [Abstract][Full Text] [Related]
30. Bringing back targets to "IMPROVE" atherosclerotic cardiovascular disease outcomes: the duel for dual goals; are two targets better than one?
Michos ED; Martin SS; Blumenthal RS
Circulation; 2015 Sep; 132(13):1218-20. PubMed ID: 26330413
[No Abstract] [Full Text] [Related]
31. Response to the Letter Regarding Article, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?".
Michos ED; Martin SS; Blumenthal RS
Circulation; 2016 Mar; 133(13):e462. PubMed ID: 27022049
[No Abstract] [Full Text] [Related]
32. Statin combination therapy and cardiovascular risk reduction.
Toth PP; Farnier M; Tomassini JE; Foody JM; Tershakovec AM
Future Cardiol; 2016 May; 12(3):289-315. PubMed ID: 27079178
[TBL] [Abstract][Full Text] [Related]
33. Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia.
Toth PP; Catapano AL; Farnier M; Foody J; Tomassini JE; Jensen E; Polis AB; Hanson ME; Musliner TA; Tershakovec AM
Am J Cardiol; 2016 Dec; 118(12):1812-1820. PubMed ID: 27756478
[TBL] [Abstract][Full Text] [Related]
34. [ANMCO Position paper: Clinical management of hypercholesterolemia in patients with acute coronary syndrome].
Colivicchi F; Gulizia MM; Arca M; Abrignani MG; Perna GP; Mureddu GF; Nardi F; Riccio C;
G Ital Cardiol (Rome); 2016 Jun; 17(6):456-61. PubMed ID: 27311088
[TBL] [Abstract][Full Text] [Related]
35. Letter by Robinson Regarding Articles, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?" and "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
Robinson JG
Circulation; 2016 Mar; 133(13):e461. PubMed ID: 27022048
[No Abstract] [Full Text] [Related]
36. Ezetimibe/simvastatin.
Montecucco F; Quercioli A; Mach F
Expert Opin Drug Saf; 2009 Nov; 8(6):715-25. PubMed ID: 19968571
[TBL] [Abstract][Full Text] [Related]
37. Is there a problem with ezetimibe or just ENHANCEd hype?
Whayne TF
Angiology; 2008 Dec-2009 Jan; 59(6):661-3. PubMed ID: 18796445
[No Abstract] [Full Text] [Related]
38. Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe.
Kater AL; Batista MC; Ferreira SR
Metabolism; 2010 Jun; 59(6):921-6. PubMed ID: 20199786
[TBL] [Abstract][Full Text] [Related]
39. Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.
Serban MC; Banach M; Mikhailidis DP
Expert Opin Pharmacother; 2016; 17(3):369-80. PubMed ID: 26559810
[TBL] [Abstract][Full Text] [Related]
40. Did we IMPROVE-IT: thoughts on LDL targeting post-trial?
Packard C; Stezhka T
Expert Rev Cardiovasc Ther; 2015 May; 13(5):465-6. PubMed ID: 25865021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
